The day in conversation for 2026-11-01

The discussion: Tom: I think the core issue with that HTA paper is how strongly the estimand dictates whether we can actually move an effect across different patient populations without losing validity. Jane: Exactly. If marginal effects are inherently population-dependent unless you satisfy some strict structural conditions, then relying on pooled estimates becomes a very risky assumption for decision-making. Lu: That reminds me of the earlier discussion we had about heterogeneity in treatment effect estimation; I wonder if this paper provides a more rigorous framework than what we’ve used when combining those subgroups. Meng: But are we really suggesting that *all* indirect comparisons fail transportability if the conditions aren't met, or is it just that the sensitivity to population structure changes? Lalam: It seems like the specific nature of the effect—is it additive or multiplicative—is a huge factor determining if those conditions are even remotely plausible. Tom: Speaking of combining data, I found the Bayesian meta-analysis paper interesting because it specifically tackles how to recover interaction inferences when we only have published subgroup data that might not perfectly align with our current modeling assumptions. Jane: That adjustment for variation is key, but does that method introduce its own set of biases when estimating the baseline effect before accounting for the subgroup contribution? Lu: I’m concerned about the computational cost of running those complex adjustments across dozens of trials; how scalable is this approach for a larger evidence base? Meng: Maybe the privacy paper offers a practical angle, though. Differentially Private Covariate Balancing C